Shots:
- The approval is based on data from two P-III studies i.e SELECT-PsA 1 & 2 evaluating the safety & efficacy of Rinvoq vs PBO in 2,000+ patients with active PsA who have had an inadequate response to methotrexate or other DMARDs
- The studies met their 1EPs of ACR20 response @12wks., Rinvoq (15mg) showed non-inferiority to adalimumab for ACR20 response, improvements in HAQ-DI & skin symptoms (PASI 75), a greater proportion of patients achieved minimal disease activity
- The safety profile was consistent with previously reported data in RA with no new safety risks observed. Rinvoq is a selective & reversible JAK inhibitor that interferes with the JAK-STAT signaling pathway
Click here to read full press release/ article | Ref: AbbVie | Image: AbbVie
The post AbbVie’s Rinvoq (upadacitinib) Receives the Health Canada’s Approval for the Treatment of Psoriatic Arthritis first appeared on PharmaShots.
